Fundraising Fox
🦊/Companies
Sign in

Pieris Pharmaceuticals

Boston, US · Founded 2013 · Nevada corporation · 3 known investors

Find your way into Pieris Pharmaceuticals

220 people in our graph share verified history with the Pieris Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

John McCulloughunlockedknows Darlene Deptula-Hicks · together at The Tuck School of Business at Dartmouth (overlapped)
×2knows the team · via F-star Therapeutics, Inc.
×2knows the team · via Red Ridge Bio
knows the team · via Lytix Biopharma
×2knows the team · via University of Valencia
×2knows the team · via The George Washington University Law School
Biotech

Founders & leadership

DDDarlene Deptula-Hicks
Darlene Deptula-HicksinSr. Vice President & Chief Financal Officer2014–2017Darlene Deptula-Hicks is an executive officer at Pieris Pharmaceuticals with background in biotech and pharmaceutical finance, including prior CFO responsibilities and experience in capital raising, public company compliance, and M&A transactions across life sciences companies.
SS
Stephen S. YoderinPresident and CEO2010–2024Stephen S. Yoder is an executive officer and director at Pieris Pharmaceuticals with expertise in biotech-pharma business development, intellectual property, and oncology and immunology drug development.
DMDarlene M. Deptula-Hicks
Darlene M. Deptula-HicksinSr. Vice President & Chief Financal Officer2014–2017Darlene M. Deptula-Hicks is Acting Chief Financial Officer of Pieris Pharmaceuticals and brings experience in biotech and pharmaceutical finance, including public and private company leadership, capital raising across equity and debt markets exceeding $350 million, and merger and acquisition transactions.

Board

CKChau Khuong
Chau KhuonginBoard directorPartner at OrbiMed
CT
Christina TakkeBoard director
SP
Steven PrelackBoard director
MR
Michael RichmanBoard director
JB
Jean-Pierre BizzariBoard director

Investors · 3

Biotechnology Value Fundreported · 2 sourcesSan Francisco
Frazier Life Sciencesreported · 2 sourcesPalo Alto
OrbiMedreportedNew York · $1M – $75Mvia Chau Khuong · board

Reported raises · per SEC filings

Form D private placements

$102.1M disclosed across 4 rounds · 2014–2019

▶$32MraisedNov 2019 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen S. YoderExecutive Officer, Director
  • Ahmed MousaExecutive Officer
  • James GeraghtyDirector
  • Michael RichmanDirector
  • Ann Barbier, M.D., Ph.D.Director
  • Hitto Kaufmann, Ph.D.Executive Officer
  • Christopher KiritsyDirector
  • Peter Kiener, D.Phil.Director
  • Matthew L. Sherman, M.D.Director
  • Maya R. Said, Sc.D.Director
  • Tom BuresExecutive Officer
  • Jean-Pierre Bizzari, M.D.Director
Offering amount
$32M
Amount sold
$32M
Sales commissions
$796.1K
Placement agents
William Blair & Company
First sale
Nov 2019
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.5MraisedJun 2016 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Darlene Deptula-HicksExecutive Officer
  • Steven PrelackDirector
  • Chau KhuongDirector
  • Michael RichmanDirector
  • Stephen S. YoderExecutive Officer, Director
  • Jean-Pierre BizzariDirector
Offering amount
$16.5M
Amount sold
$16.5M
Sales commissions
$1.1M
Placement agents
Trout Capital LLC, Oppenheimer & Co. Inc., Cowen and Company, LLC
First sale
Jun 2016
Incorporated
Corporation, Nevada, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.6MraisedDec 2014 · 139 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Chau KhuongDirector
  • Darlene M. Deptula-HicksExecutive Officer
  • Steven PrelackDirector
  • Christina TakkeDirector
  • Michael RichmanDirector
  • Stephen S. YoderExecutive Officer, Director
Offering amount
$13.6M
Amount sold
$13.6M
Minimum investment
$2K
Sales commissions
$1M
Placement agents
Trout Capital LLC, Dinosaur Securities, L.L.C., American Portfolios Financial Services, Inc.
First sale
Dec 2014
Incorporated
Corporation, Nevada, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40MraisedDec 2014 · 21 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael RichmanDirector
  • Christina TakkeDirector
  • Chau KhuongDirector
  • Darlene M. Deptula-HicksExecutive Officer
  • Steven PrelackDirector
  • Stephen S. YoderExecutive Officer, Director
Offering amount
$40M
Amount sold
$40M
First sale
Dec 2014
Incorporated
Corporation, Nevada, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Pieris Pharmaceuticals stock (US72016P1057): Company update after recent market dataad-hoc-news.de · May 2026Pieris Pharmaceuticals stock: What you should know before buying nowad-hoc-news.de · Apr 2026Palvella Therapeutics Secures $79M Funding, Completes Merger with Strong Cash Position Through 2027 | PVLA Stock Newsstocktitan.net · Dec 2024Pieris Pharmaceuticals announces board changes and merger update By Investing.cominvesting.com · Dec 2024Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023 - BioSpacebiospace.com · May 2023Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million - Gilde Healthcaregildehealthcare.com · Dec 2014

Frequently asked questions

Who are Pieris Pharmaceuticals's investors?
Pieris Pharmaceuticals's investors include Biotechnology Value Fund, Frazier Life Sciences, OrbiMed.
How much funding has Pieris Pharmaceuticals raised?
Pieris Pharmaceuticals has disclosed $102.1M raised across 4 rounds.
Where is Pieris Pharmaceuticals headquartered?
Pieris Pharmaceuticals is headquartered in Boston, US.